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Estrogen and progesterone are the defining hormones of normal female development, and both play critical
roles in breast carcinogenesis. Cyclin D1 is a breast cancer oncogene whose amplification is linked to poor
prognosis in estrogen and progesterone receptor-positive breast cancers. Here we report that cyclin D1
regulates progesterone receptor expression, consequently enhancing responses to estrogen and progesterone.
Estrogen treatment of cyclin D1 transgenic mice increased progesterone receptor expression and induced
mammary hyperplasias that were stimulated by progesterone and blocked by a progesterone antagonist.
Progesterone receptor levels decreased in cyclin D1 knockout mice. Cyclin D1 regulated progesterone receptor
expression through a novel estrogen- and cyclin D1-responsive enhancer in DNA encoding part of the 3
untranslated region of the progesterone receptor gene. Small inhibitory RNAs for cyclin D1 decreased pro-
gesterone receptor expression and estrogen receptor binding to the 3 enhancer region in human breast cancer
cells. Since estrogen and progesterone regulate cyclin D1, our results suggest that cyclin D1’s participation in
a feed-forward loop could contribute to increased breast cancer risks associated with estrogen and progester-
one combinations. Additionally, its regulation of the progesterone receptor identifies a novel role for cyclin D1
in ovarian hormone control of breast development and breast carcinogenesis.
We have long known that ovarian hormones control normal
breast development (13). Likewise, the connection between
ovarian hormones and breast cancer was first therapeutically
exploited over 100 years ago (3). While estrogen and proges-
terone (Pgr) combine to regulate normal breast development
during pregnancy, the Women’s Health Initiative study of hor-
mone replacement has clearly demonstrated an increased
breast cancer risk when progestins are combined with estrogen
(7). This result reinvigorated the view that combinations of
progesterone with estrogen can be carcinogenic.
Cyclin D1 (CCND1) is a multifunctional G1-phase cyclin
whose regulatory effects are particularly important in breast
development and cancer (44). The cloning of cyclin D1 at
11q13 translocation breakpoints in parathyroid and mantle cell
tumors was strong evidence of its oncogenic function, and
evidence indicating that D1 was a G1 cyclin was a key finding
that linked cancer to perturbations of the cell cycle. Extensive
evidence links cyclin D1 to cyclin-dependent kinase regulation
of the cell cycle (27), although a recent report demonstrates
that it also acts in transcriptional control (4). 11q13 amplifica-
tion has been repeatedly demonstrated in breast cancers (22)
where CCND1 overexpression has been linked to estrogen and
progesterone receptor (PR) status. This linkage was first at-
tributed to cyclin D1’s regulation by estrogen and progesterone
(12, 37). In this model, CCND1 is proposed to contribute to
poor treatment response of estrogen receptor (ER)-positive
tumors by acting downstream to promote hormone agonist-
and antagonist-independent proliferation (47).
The connection between poor patient outcome and cyclin
D1 status in ER-positive breast cancers also led to explorations
of a second potential explanation for cyclin D1-ER linkage.
Identification of a potential ER coactivator interaction motif in
the cyclin D1 protein suggested that CCND1 can interact with
ER coactivators to activate estrogen receptor binding elements
(ERE) in a ligand-independent manner (29, 52). Importantly,
this direct activation of EREs by CCND1 was not inhibited by
antiestrogens (52) and did not require an interaction between
cyclin D1 and its associated cyclin-dependent kinases (CDK4/
CDK6). This CDK4/CDK6 independence is potentially impor-
tant, since CDK activity is not always increased in cyclin D1-
associated breast cancers (45). Importantly, knock-in of CDK-
independent cyclin D1 repairs a mammary developmental
defect seen during pregnancy in cyclin D1 knockout mice,
specifically confirming cyclin D1’s potential CDK-independent
functions (23).
A study employing cyclin D1 transgenic mice provided the
first in vivo demonstration that cyclin D1 is an oncogene (46).
These mice demonstrate extensive preneoplastic hyperplasias
that precede tumor onset by months. Using laser-capture mi-
crodissection and microarray analysis, we identified genes that
were upregulated in invasive tumors compared with normal or
hyperplastic tissues (48). Remarkably, these genes were re-
sponsive to estrogen and responded to cyclin D1 in a CDK4/
CDK6-independent manner, and the cyclin D1 and estrogen
effects were additive. This result suggested that, as a third
explanation for their association in breast cancer, cyclin D1
and the ER might share target genes. To investigate this pos-
sibility, we treated cyclin D1 transgenic mice with estrogen,
causing hyperplasias that exhibited increased progesterone re-
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ceptor expression. We now report that cyclin D1 and estrogen
regulate progesterone receptor expression, which identifies a
mechanism that may couple the effects of estrogen and pro-
gesterone in breast tissues and explain the tight association
between cyclin D1 expression and hormone receptor status in
breast cancer.
MATERIALS AND METHODS
Animals and histology. Mouse mammary tumor virus (MMTV) cyclin D1
transgenic mice were maintained as previously described (46). Pellets containing
17-estradiol (Innovative Research) (0.72 mg/pellet) (49), mifepristone (RU486)
(Innovative Research) (35 mg/pellet) (34), and/or progesterone (Innovative Re-
search) (10 mg/pellet) (40) were implanted into wild-type (WT) and cyclin D1
transgenic mice 60 days of age, and sham-treated animals were used as controls.
This estradiol dose provides twice the physiologic levels found during estrus but
1/20th of the levels found during pregnancy (30). The progesterone dose is
sufficient to regulate ductal development in ovariectomized mice (40). The mifep-
ristone dose blocks tumor development in BRCA/ mice (34). Whole mounts
were prepared 2 months later by dissecting the mammary fat pad from the pelt,
fixing in 10% buffered formalin, staining with carmine red, dehydrating in graded
series of alcohol, and clearing with xylene. Eight animals each were used for the
wild-type and cyclin D1 transgenic mouse groups or were subjected to sham or
estradiol treatment. Morphometry was performed by counting structures in three
photomicrographs of each of the 32 resulting whole-mount preparations. Num-
bers of branches (B), termini (T), and lobuloalveolar structures (LAS) were
counted and totaled for each image. The means and standard errors for the
numbers of branches, termini, and alveolar structures per image were then
plotted. Four animals each were used for the experiments combining estradiol,
mifepristone, and/or progesterone treatment. Mammary glands were fixed in
10% formaldehyde in phosphate-buffered saline (PBS) for routine hematoxylin
and eosin staining histology. Additional mammary glands from the same mice
were harvested for RNA and protein analysis. Cyclin D1 knockout mice (JAX
002537 mice; Jackson Laboratories) and matched controls were sacrificed at 8
weeks of age and after 12 days of pregnancy, and the mammary tissues were used
for RNA and protein analysis.
RNA and protein expression analysis. mRNA levels in cellular RNA isolated
from the indicated cells or mouse tissues by the use of Trizol (Invitrogen) were
analyzed. mRNA was reverse transcribed into cDNA and converted to double-
stranded DNA (dsDNA); quantitative real-time PCRs (qRT-PCR) were per-
formed as described previously (48). Table 1 presents primer and probe se-
quences.
For Western analyses, 50 g of protein sample was subjected to sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred
to polyvinylidene difluoride (PVDF) membranes. Membranes were incubated
with rabbit polyclonal anti-cyclin D1 (48), anti-PR antibody (C-20; Santa Cruz,
Santa Cruz, CA), anti-beta-catenin (BD Transduction Laboratories, San Jose,
CA), anti-IER3 (Abcam Inc., Cambridge, MA), anti-etv5 (Abnova Corp., Taipei
City, Taiwan), anti-mitogen-activated protein kinase (anti-MAPK) (K-23; Santa
Cruz Biotechnology, Santa Cruz, CA), or antiactin (Chemicon International,
Temecula, CA) as indicated. The secondary antibodies used were purchased
from Santa Cruz or were those included in an enhanced chemiluminescence
detection kit (Amersham).
Proliferating T47D cells were incubated in phenol red-free Dulbecco’s mod-
ified Eagle’s medium (DMEM) with 5% charcoal stripped serum for 3 days
before transient transfections were performed. Cyclin D1 (Ambion) and scram-
ble (Dharmacon D-1205-20) small interfering RNAs (siRNAs) were transfected
using NeoFX (Applied Biosystems). To demonstrate the knockdown efficiency of
the siRNAs, cells were harvested 48 h after transfection and subjected to West-
ern blot analysis. We also stably reduced cyclin D1 expression in T47D cells by
the use of a lentiviral construct expressing a short hairpin RNA (shRNA) tar-
geted to CTCTAAGATGAAGGAGACCAT in exon 2 of cyclin D1 (RNAi
consortium no. TRCN0000040040).
ZR-75-1, CAMA, HCC1428, BT483, and MCF 7 breast cancer cells were
grown under the conditions indicated by the supplier (ATCC). They were also
transiently transfected with scramble or small inhibitory RNA for cyclin D1
(siCCND1) siRNAs as described for the T47D cells. Western blot analysis and
quantitative real-time PCRs (qRT-PCR) were performed as described above.
ChIP and electrophoretic mobility shift experiments. We performed chroma-
tin immunoprecipitation (ChIP) as previously described (48). We evaluated
estrogen receptor genomic binding in T47D cells grown in phenol red-free
DMEM with 5% charcoal-stripped serum for 3 days and treated with vehicle or
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100 nM 17-estradiol for 4 h. We performed chromatin immunoprecipitation by
a method that we previously described (48). Cross-linking was performed by
adding 37% formaldehyde to reach a final concentration of 1.5% for 15 min at
25°C with gentle agitation. The reaction was stopped by adding 0.125 M glycine
for 5 min. Cells were scraped and collected by centrifugation; the pellet was
washed twice with ice-cold PBS (120 mM NaCl, 2.7 mM KCl, 10 mM phosphate
buffer, pH 7.4) and twice with immunoprecipitation (IP) buffer (150 mM NaCl,
5 mM EDTA, 1% Triton X-100, 0.5% NP-40, 50 mM Tris-HCl [pH 7.5], 0.5 mM
dithiothreitol [DTT]) and resuspended with IP buffer supplemented with 0.5%
SDS and protease inhibitor cocktail (Roche). Sonication was performed until the
desired DNA fragment sizes were reached. The lysate was then subjected to
centrifugation at 12,000  g for 10 min. The supernatant was collected and
diluted 5-fold with IP buffer. For immunoprecipitation, anti-ER antibody (HC-
20) from Santa Cruz or an equal concentration of normal rabbit serum was
added to the lysate and incubated at 4°C overnight with agitation. Protein A
Sepharose beads (Amersham) were added to the mixture and incubated for 1 h.
The beads were collected by centrifugation and washed twice with IP buffer,
twice with high-salt IP buffer (500 mM NaCl, 5 mM EDTA, 1% Triton X-100,
0.5% NP-40, 50 mM Tris-HCl [pH 7.5], 0.5 mM DTT), twice with stringent wash
buffer (10 mM Tris-HCl [pH 7.5], 0.25 M LiCl, 0.5% NP-40, 0.5% sodium
deoxycholate, 1 mM EDTA), and twice with Tris-EDTA (TE) buffer (10 mM
Tris-HCl, 0.1 mM EDTA). The bound fraction was eluted in elution buffer (TE
buffer with 1% SDS) at 65°C for 10 min. Cross-links were reversed by incubating
the eluate at 65°C for 6 h. Samples were treated with proteinase K at 45°C for 1 h
and subjected to phenol-chloroform extraction and ethanol precipitation. The
primer sets used in quantitative PCRs (qPCR) are listed in Table 2.
T47D cell nuclear extracts were obtained and analyzed using previously pub-
lished methods (9). Gel shift activity for DNA binding proteins was determined
using electrophoretic mobility shift assay (EMSA) binding buffer (20 mM
HEPES [pH 7.5], 50 mM KCl, 7.5 mM MgCl2, 0.2 mM EDTA, 10% glycerol, 0.5
mM DTT) and 2 ng/l poly(dI-dC) as a nonspecific competitor. Complexes
formed in binding buffer were resolved on a 4% nondenaturing polyacrylamide
gel containing 0.5 Tris-borate-EDTA (TBE) buffer at 4°C. Double-stranded
oligonucleotides were purified by polyacrylamide gel electrophoresis and labeled
using [-32P]ATP and polynucleotide kinase. Each binding reaction mixture
contained between 0.1 and 0.5 ng of labeled oligonucleotides. Competition
experiments were performed using a 200-fold molar excess of unlabeled oligo-
nucleotides. Oligonucleotide sequences are listed in Table 2.
Reporter constructs and transfections. Transient transfections were per-
formed using T47D cells for the majority of the reporter assays (but see Fig. 8,
which shows the results of experiments in which we used MCF7 cells). The
transient siCCND1 transfections were performed as described above. Cyclin D1
overexpression was accomplished using the plasmids pRC-CMV-cyclin D1 and
pRC-CMV-mutant K112E as previously described (48). The plasmids hPRAB,
hPRA, and hPRB were gifts from I. De Vivo (17). The 3 estrogen response
element (ERE) luciferase plasmid was obtained from Addgene (14). The 1.3-kb
nucleotide portion of the 3 untranslated region (UTR) of the progesterone
receptor gene (94788 to 96092 relative to the B from the transcription start
site [TSS]) was amplified by PCR using primers PR3F114788IF (GTCTG
GATCCGTCGACGTCCTAAATTGCTTATCCTTACTTCACTAAG) and
PR3R116092IF (AAGGGCATCGGTCGACTGGCAAAAAGCTTGAAACCA
CTGCTGTC) and cloned to SalI-digested pGL2 reporter vectors by the use of
an In-Fusion cloning kit (Clontech). To insert the 3 UTR in the opposite
orientation, the same nucleotide portion was amplified using primers
PR3F114788IV (AAGGGCATCGGTCGACGTCCTAAATTGCTTATCCTTA
CTTCACTAAG) and PR3R116092IV (GTCTGGATCCGTCGACTGGCAAA
AAGCTTGAAACCACTGCTGTC) and similarly cloned into pGL2.
To clone hPR AB-CER, primers PR3F115435IF and PR3R115672IF were
used to amplify T47D genomic DNA. To clone hPR AB-REC, primers
PR3F115435IV and PR3R115672IV were used. PCR fragments were inserted
into the SalI site of hPR AB plasmid by the use of an In-Fusion cloning kit
(Clontech). To construct hPR AB-3XCER, a primer PR-P1F- and primer
PR3R115672IF-amplified fragment was similarly cloned to the hPR AB SalI site.
The second copy of the central element-containing region (CER) was inserted in
the same site by a primer PR-P2F- and primer PR3R115672IF-amplified frag-
ment. This step was then repeated to introduce the third copy of CER. To move
the tandem CERs to the proximal position upstream of hPR promoter, the
3XCER fragment was amplified from plasmid hPR AB-3XCER by primers
IF-3xCERXhoF and IF-3xCERXhoR and cloned to the XhoI-linearized hPR
AB plasmid by the use of an In-Fusion kit. hPRAB-CER1 and hPRAB-
CER2 were mutated from hPRAB-CER by the use of a Stratagene
QuikChange Lightning site-directed mutagenesis kit. All constructs were
validated by sequencing. The primer sequences used for cloning were as
follows: for PR3F115435IF, GTCTGGATCCGTCGACATTCCAAGGCAG
AGCTCAGG; for PR3R115672IF, AAGGGCATCGGTCGACCTTAAAAA
TAATGCCTCTCCC; for PR3F115435IV, AAGGGCATCGGTCGACATTCCA
AGGCAGAGCTCAGG; for PR3R115672IV, GTCTGGATCCGTCGACCTTAA
AAATAATGCCTCTCCC; for PR-P1F, GTCTGGATCCGTCGAGACGTCATT
CCAAGGCAGAGCTCAGG; for PR-P2F, TATTTTTAAGGTCGATGCATATT
CCAAGGCAGAGCTCAGG; for IF-3xCERXhoF, CATTC A G A A
TCTCGAGCTGGATCCGTCGAGACGTC; and for IF-3xCERXhoR, GGC
ATTTCCACTCGAGGGCATCGGTCGACCTTAA.
Cells were transfected in 96-well plates with 200 ng of luciferase reporter
plasmids by the use of Lipofectamine 2000 (Invitrogen) with 0.5 ng of pCMV-
renilla as a control. Cells were treated with 100 nM estradiol 24 h after trans-
fection and assayed using a dual-luciferase reporter assay system (Promega) after
24 h of treatment.
RESULTS
Estradiol treatment enhances mammary hyperplasia in cy-
clin D1 transgenic mice. Since cyclin D1 is particularly associ-
ated with hormone receptor-positive cancers, we sought to
determine whether constitutive cyclin D1 expression would
accelerate the response to estrogen in an animal model. We
stimulated mammary proliferation using wild-type and
CCND1 transgenic mice and continuous-release 17-estradiol
TABLE 2. Primers used for chromatin immunoprecipitation and electrophoretic mobility shift experiments
Position with respect
to TSS Amplified region ChIP-PCR forward primer ChIP-PCR reverse primer
56 120 to 0 CAGAATAACGGGTGGAAATG TGGCCAGACAGCTTTCTAAC
90 41 to 150 TGTGCGTGTGGGTGGCATTC CGAAGATCTCAGATCCCAGT
326 276 to 375 GAGAGCTTCACAGCATGCAC CTTGAGTGGCTGCGGCTGCG
580 521 to 640 CGACAGCCACAGTTCCCCTG GTGTTGAATGTGGCTGGACCG
650 606 to 710 GGTGGAGATCCCTCCGGTCC CTCCAGGAGGAGGGAAAAGG
745 701 to 790 CCTCCTGGAGACGGGGGAGG GCCCGCCACGTGGGGAGCCC
1233 1181 to 1285 CTTCCCGAAGATCCACCGGC GGCAGCTGCCGTCCCGGAGC
51200 51128 to 51307 GAGTTATTTGATTTCTTCGTTG GAAGATGGAAGCAGAACACC
79800 79733 to 79903 GTGTATTGTGTGTGATGCAAG GTTACTTGAACTCACTCACTTG
95585 95538 to 95660 CTAGTCCCAGAATGTCAGCC GCCTCTCCCATGTCTCCATG
EMSA probes Designated
95585 585 CTGTATGTCATGCTGACCTTATTGTTAAACAC
95585 mutant 585 CTGTAGATCTTGCGTCTATTATTGTTAAACAC
95585 core 585core CGTGTCATGCTGACCGA
95585 mutant core 585core GCAGCTTATGCTGATAG
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(E2) pellets (49). We initiated treatment at 2 months of age
and evaluated the proliferative response of mammary glands 2
months later using whole-mount and histologic assessments.
Estradiol and cyclin D1 and their combination all caused dif-
ferent changes in mammary glands (Fig. 1). Ducts in untreated
wild-type mice had a simple branching structure (Fig. 1A and
B) that terminated in single end-bud structures (see letter T in
Fig. 1A). Estradiol treatment led to dilated ducts and aberrant
buds at the termini of ducts in wild-type mice (Fig. 1B and F).
Cyclin D1 overexpression increased levels of both side branch-
ing and terminal acinar structures in the transgenic mice (Fig.
1C and G). The combination of estradiol treatment with cyclin
D1 overexpression caused more marked changes. First, ducts
were dilated and showed multiple abnormally enlarged buds
that were reminiscent of normal alveolar structures (see
“LAS” in Fig. 1D; also see Fig. 1H). Second, multiples of such
alveolar structures were found along the sides of ducts,
whereas no such structures were found in similar locations in
E2-treated wild-type mice, and those found in untreated
CCND1 mice were small. These effects combined to produce
extensive alveolar hyperplasia in E2-treated CCND1 trans-
genic mice. We analyzed whole mounts and histology using a
total of eight mice from each of the four groups and performed
morphometric analyses as described in Materials and Methods.
FIG. 1. Alveolar structure numbers increase in mammary tissues constitutively expressing cyclin D1 after treatment with estrogen. Continuous
release estradiol pellets were implanted subcutaneously into wild-type mice (B and F) and cyclin D1 transgenic mice (D and H) at 2 months of
age as described in Materials and Methods. Control mice (A and E) were subjected to sham operations at the same time as control cyclin D1
transgenic mice (C and G). Mammary glands were harvested 2 months later for analysis using whole-mount preparations (A to D) and for routine
hematoxylin and eosin staining histology (E to H). (A to D) Whole-mount photomicrographs (10). (A) Wild-type mice (WT); (B) estradiol
(E2)-treated WT mice; (C) transgenic MMTV-CCND1 mice (CCND1); (D) MMTV-CCND1 mice treated with estradiol (CCND1 E2). (E to H)
Histologic photomicrographs (40). (E) Wild-type mice (WT); (F) estradiol (E2)-treated WT mice; (G) transgenic MMTV-CCND1 mice
(CCND1); (H) MMTV-CCND1 mice treated with estradiol (CCND1 E2). (I) Morphometric counts. We harvested whole-mount preparations for
eight mice in each of the four groups (wild-type sham, wild-type E2, CCND1 sham, and CCND1 E2). Morphometric analyses were then performed
by counting structures in three photomicrographs of each of the 32 whole-mount preparations. Numbers of branches, termini, and lobuloalveolar
structures (LAS) were counted on coded photographs and totaled for each image. The means and standard errors for the numbers of branches,
termini, and alveolar structures per image are shown.
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Numbers of LAS in E2-CCND1 mice increased at least 10-fold
over LAS in the wild-type mice and 5.8-fold over LAS in
E2-treated mice (P  0.001) (Fig. 1I).
Estradiol treatment increases progesterone receptor expres-
sion and signaling in cyclin D1 transgenic mice. We next
assessed expression of cyclin D1, the ovarian hormone recep-
tors, and several target genes to identify genes whose altered
expression accompanied these histologic changes. Using spe-
cies-specific primers, we found that levels of murine CCND1
mRNA increased in response to transgene treatment or to E2
treatment but that combining the two treatments did not cause
additive increases (Fig. 2A). Since the human cyclin D1 trans-
gene was not present in the wild-type mice, we further evalu-
ated the increase in its mRNA value with respect to the murine
wild-type value and found that the transgenic CCND1 value
equally increased in the absence and presence of the E2 stim-
ulus, as expected, since the MMTV element does not respond
to the presence of estrogen (32). Thus, estradiol was not acting
simply to induce expression of the CCND1 transgene.
We then evaluated hormone receptor mRNAs and found
that ER-alpha mRNA levels were only minimally affected by
either estradiol treatment or transgene expression (Fig. 2B).
Instead, progesterone receptor mRNA levels increased in re-
sponse to the presence of both estradiol and cyclin D1 and
especially increased in the E2-treated CCND1 mice to a level
that was 4-fold above the wild-type value (Fig. 2B [PR]; P 	
0.001). The PR mRNA is transcribed as a full-length BA tran-
script and a 300-nucleotide-shorter A transcript. The B-specific
extension can be identified using PCR primers specific for its
unique 5 region. As previously reported (1), PR expression in
these nonpregnant mammary samples was nearly entirely the
PR A transcript. Cyclin A2 (CCNA2) was evaluated as a po-
tential CDK4/E2F target gene, and its expression increased
20-fold in level in response to CCND1 expression (Fig. 2C).
The combination of estradiol with CCND1 did not further
increase CCNA2 numbers. We also evaluated expression of
two candidate CCND1 targets that were found to be associated
with tumor invasion in our previous study (48) (Fig. 2C). Ex-
pression of both the immediate-early response 3 (IER3) and
ets variant 5 (ETV5) mRNAs increased in response to the
combination of cyclin D1 and estrogen, along with that of the
increased progesterone receptor mRNA. Since IER3 is a
known progesterone target (35), the ETV5 and IER3 increases
may have resulted as a response to the cyclin D1-induced
increase in PR rather than as a direct effect of CCND1 and E2
on regulation.
To confirm the mRNA results, we performed immunoblot
analyses for the progesterone receptor as well as for several
progesterone receptor and cyclin D1 target genes (19, 36) (Fig.
2D). Progesterone receptor protein levels generally paralleled
mRNA changes, and only the 94-kDa PR A isoform was seen,
as previously described (1). PR levels clearly increased in the
cyclin D1-expressing transgenic tissues. -Catenin, a known
target of PR function, increased in level only in the E2-CCND1
mice. This increase in -catenin levels, together with the in-
creased PR levels, suggested that the E2-CCND1 combination
enhanced both PR expression and PR function (16). Indeed,
the histology of the E2-CCND1 mice resembles that seen in
PR overexpression (41) and in increased -catenin signaling
(26). Both the IER3 and ETV5 protein levels increased in
response to the CCND1 transgene (Fig. 2D), although in-
creases in IER3 and ETV5 protein numbers did not fully
match the mRNA increases, suggesting that additional post-
transcriptional mechanisms may limit additional estrogen-in-
duced expression. Taken together, our results suggest that
combining E2 with constitutive CCND1 expression causes a
hyperplastic abnormality in virgin mice and that that abnor-
mality is accompanied by increased PR and PR signaling in
those mice.
Loss of cyclin D1 in knockout mice causes mammary growth
failure during pregnancy, when progesterone receptor signal-
ing is most critical for normal reproductive development (43).
To determine whether PR expression is decreased in CCND1
knockout mammary glands, we measured PR mRNA and pro-
tein levels in glands harvested from virgin wild-type and
CCND1/ mice at 8 weeks of age and in glands harvested
from wild-type and CCND1/ mice at 12 days of pregnancy
(Fig. 2E and F). Loss of cyclin D1 led to decreased PR mRNA
levels in both stages. PR protein changes paralleled the
changes in mRNA, and, as expected, we observed a PR B
isoform band at 114 kDa in pregnant tissues. The results seen
with a keratin 19 blot experiment suggested that the observed
changes were not merely the result of changes in luminal cell
composition in the knockout tissues. PR expression was in-
creased in tumors in the cyclin D1 transgenic mice (Fig. 2G
and H).
Estrogen-enhanced mammary hyperplasia is further regu-
lated by progesterone agonists and antagonists in cyclin D1
transgenic mice. Given this evidence for increased PR signal-
ing and the phenotypic changes that were consistent with a
shift toward enhanced PR function in estrogen-treated cyclin
D1 transgenic mice, we next sought to determine whether
progesterone (Pgr) agonists or antagonists would enhance or
block effects of the E2-CCND1 combination in virgin mice
(Fig. 3). First, mifepristone (RU486) blocked much of the
effect of E2 on CCND1 mice (Fig. 3F and H versus Fig. 3B and
D). Importantly, the addition of progesterone pellets to E2 and
CCND1 markedly stimulated the lobuloalveolar development
beyond that achieved by E2 treatment and clearly increased
hyperplasia compared to the results seen with E2-Pgr-treated
wild-type mice (compare Fig. 3J and L to Fig. 3I and K). In
contrast, treatment of wild-type and CCND1 mice with pro-
gesterone alone revealed few differences (Fig. 3M and O and
Fig. 3N and P, respectively). We repeated these experiments
using mice subjected to ovariectomy at 7 weeks of age. The
histologic changes that accompanied estrogen and progester-
one treatment of wild-type and cyclin D1 transgenic mice were
not affected by ovariectomy, suggesting that these phenotypic
changes were not dependent on endogenous ovarian hormone
production (not shown).
Identification of a 3 estrogen receptor binding element in
the progesterone receptor gene that responds to cyclin D1 and
estrogen. To determine whether the regulatory effects of CCND1
and estrogen on PR expression could also be found in human
cells, we tested the effects of a small inhibitory RNA for cyclin D1
(siCCND1) on PR expression in T47D breast cells. Progesterone
receptor mRNA levels decreased 60% 
 1% in response to
siCCND1 compared to those seen with scramble siRNA-trans-
fected control cells. This decrease was seen primarily in the
shorter PR A isoform analyzed using isoform-specific primers.
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Western blot experiments confirmed that siCCND1 transfections
decreased both cyclin D1 and PR levels (Fig. 4A), and image analysis
confirmed a 2-fold decrease in cyclin D1 protein levels. We then
evaluated the effect of this PR change on IER3 expression and found
that it also decreased in response to decreased CCND1.
Although previous investigations failed to discover PR pro-
moter sequences that contained the canonical estrogen recep-
tor binding sequence (agGtCAnnnTGaCct; uppercase indi-
cates conserved sites) (6), several investigators identified
alternative promoter elements that responded to estrogen, in-
FIG. 2. Estradiol increases progesterone receptor expression in mammary tissues of mice constitutively expressing cyclin D1. (A) Levels of both
murine CCND1 mRNA (CCND1 M) and the human CCND1 mRNA that was used in our transgene (CCND1 H) were assessed by TaqMan-based
quantitative real-time PCRs (qRT-PCR) to evaluate cDNAs reverse transcribed from 5 g of total RNA harvested from each of the indicated
specimens 2 months after hormonal treatments. We measured mRNA and cDNA amounts at each step in the analyses and used equal amounts
of mRNA and cDNAs for each tissue and gene evaluated for each qRT-PCR. Murine cyclin D1 (CCND1 M) and human cyclin D1 (CCND1 H)
levels were determined and plotted as fold changes in the threshold value for quantitation, setting the untreated wild-type (WT) mammary sample
to a value of 1 and plotting fold changes for each of the other samples. The results for wild-type (WT), E2-treated wild-type (WT E2), CCND1
transgenic (TG-D1), and E2-treated CCND1 transgenic (TG-D1 E2) mice are indicated. The means and standard errors for 3 samples are shown.
Human CCND1 was undetectable in wild-type mice, and the murine CCND1 primer-probe set did not detect human CCND1. (B) Estrogen
receptor (ER) and progesterone receptor (PR) mRNAs were evaluated with TaqMan as described for panel A, using the specific primers and
probes listed in Materials and Methods. The PR BA mRNA is 300 nucleotides longer than the PR A transcript. PR B isoform-specific primers
were used to differentiate expression of this additional 5 sequence (34). (C) Changes in cyclin A2 (CCNA2) expression were evaluated in the same
tissues to detect possible CDK- and E2F-dependent effects. Increases for immediate-early response 3 (IER3) and ets variant 5 (ETV5), two
candidate CCND1-target mRNAs, were evaluated in the same tissues. (D) Mammary protein lysates (50 g) were probed for CCND1 (by using
an antibody that detects both human and mouse cyclin D1), the progesterone receptor (PR), -catenin, and the two candidate CCND1-target genes
for which antibodies could detect the murine protein in mammary tissues. Size markers show that numbers of the PR A isoform are increased in
the cyclin D1 transgenic mice, consistent with reports that PR A is the dominant PR isoform except during the later stages of pregnancy (1). An
actin loading control is included. Wild-type (WT) and cyclin D1 transgenic (TG-D1) genotypes are indicated. Treatment groups were subjected
to sham treatment (S) or treated with estradiol pellets (E2). (E) Progesterone receptor mRNA levels were measured in mammary tissues from
virgin (V) and 12-day-pregnant (P), wild-type (WT), and CCND1/ (D1/) mice. The mRNAs were isolated and measured as described above
for panel A. Values are plotted as means and standard deviations for two glands of each developmental stage and phenotype. (F) Protein lysates
from mammary glands of virgin (VM), 12-day-pregnant (PM), wild-type (WT), and CCND1/ (Nu) mice were probed and compared with those
of a wild-type uterine sample (Ut). In this case, both 114-kDa and 94-kDa PR bands are seen for the pregnant tissues, consistent with the reported
expression of PR B and A during pregnancy (1). The membrane was then probed for keratin 18, a luminal mammary cell marker (2), to show that
the PR changes were not due simply to changes in tissue composition. An actin loading control is shown. (G) Progesterone receptor mRNA was
measured in mammary lysates from normal mammary tissues (Normal) and tumors induced by the MMTV-cyclin D1 transgene (Tumor). The
mRNAs were isolated and measured as described above for panel A. (H) Lysates harvested from normal mammary glands (M) and cyclin
D1-transgene-induced tumors (T) were probed for PR protein and an actin loading control.
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FIG. 3. The increased estrogen-induced lobuloalveolar structures in mammary tissues constitutively expressing cyclin D1 were blocked by a proges-
terone antagonist, enhanced when progestins were added to estrogen, and did not appear in response to progestins alone. (A to H) Mifepristone blocks
estrogen effects in cyclin D1-expressing mice. The effect of treatment using continuous-release estradiol pellets was compared to the effect of treatment
using estrogen plus continuous-release mifepristone (RU486) in wild-type mice (A and C versus E and G) and MMTV-cyclin D1 mice (B and D versus
F and H) 2 months after pellet implantation at 2 months of age. Mammary glands were harvested for analysis using whole-mount preparations (10)
(A, B, E, and F) and for routine hematoxylin and eosin staining histology (40) (C, D, G, and H). (I to P) Progestins enhance estrogen’s effects on
mammary tissues constitutively expressing cyclin D1. The effect of the combination of progesterone pellets with continuous-release estradiol pellets was
compared to the effect of progesterone pellets alone in wild-type mice (I and K versus M and O) and MMTV-cyclin D1 mice (J and L versus N and P)
2 months after pellet implantation. Mammary glands were harvested from mice 4 months of age for analysis by whole-mount preparations (10) (I, J,
M, and N) and for routine hematoxylin and eosin staining histology (40) (K, L, O, and P).
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FIG. 4. Small interfering RNA (siRNA) knockdown of cyclin D1 blocks progesterone receptor expression and inhibits chromatin binding of the
estrogen receptor to a novel 3 estrogen response element in the progesterone receptor gene. (A) A small interfering RNA that knocks down cyclin
D1 (siCCND1) decreases progesterone receptor expression. T47D breast cells were transfected with siCCND1 (Si) or a scramble control (Sc), and
protein lysates were harvested 48 h later (left panel). We performed immunoblot analyses using 50 g of protein lysates for the indicated genes.
Immunoblots for cyclin D1 (CCND1), the progesterone receptor (PR) isoforms A and B, the immediate-early response gene 3 (IER-3) that we
had previously demonstrated to have responded to cyclin D1 and estrogen (48), and an actin loading control are shown. (Right panel) Isoform BA
and B transcripts of the progesterone receptor were measured using equal amounts of reverse-transcribed cDNA via isoform-specific qRT-PCR.
Isoform A levels were derived by subtracting B from AB levels. The mean and standard error fold changes from scramble to siCCND1 transfectants
are shown. (B) Analysis of cis sequences that have been reported to be estrogen control elements in the progesterone receptor gene promoters.
Sites in the progesterone promoter region where estrogen regulation of PR expression has been proposed to occur are indicated. Candidate sites
include the following: site 1, Sp1 (39); site 2, an AP1 at 90 from the PR B transcription start site (TSS) (33); site 3, a G/A 326 GATA5 breast
cancer risk polymorphism (17); site 4, an Sp1-ERE half-site (33); site 5, the PR isoform A promoter region; site 6, a second AP1 at 745 from
the PR B TSS (38); site 7, an RNA polymerase II binding site (6); and site 8, a rat promoter site that was previously shown to have responded
to E2 (20). The locations of the start (Begin) and ending (End) points for the PCR primers used in these studies are indicated, along with the
numbering system (Site) that identifies each site. We performed ChIP-PCR for ER binding as previously described (48). Anti-ER ChIP-PCR
signals are plotted as a fraction of the input DNA for each reaction, subtracting the minimal ChIP-PCR backgrounds obtained using a nonspecific
control serum from the ER signal. We measured ER ChIP-PCR DNA levels in cells transfected with a scramble control (scr) or an siCCND1
(siD1) oligonucleotide. Transfectants were treated with vehicle control (V) or estradiol (E). At each site, the bars depict the ER signal for
scramble plus vehicle (scr), scramble plus E2 (scr E2), siCCND1 plus vehicle (siD1), and siCCND1 plus E2 (siD1 E2). (C) Locations of three
conserved, canonical estrogen receptor binding sequences in the progesterone receptor gene. The progesterone receptor gene structure is shown
diagrammatically using the UCSC genome browser to plot its exons. A homology plot from the genome browser is shown; an arrow identifies the
region in the 3 UTR of the gene that is the most highly conserved part other than its exons. The locations of the three canonical estrogen receptor
binding elements that are conserved across mammalian species are indicated (ERE 1, 2, and 3). (D) Chromatin immunoprecipitation (ChIP)
identified a novel ER-binding site in the DNA encoding the 3 untranslated region (UTR) of the PR gene whose ER binding is uniquely stimulated
by estradiol and blocked by an inhibitory siCCND1 oligonucleotide. We performed ChIP-PCR for ER binding at the three ERE sites as described
for panel C. Anti-ER ChIP-PCR signals are plotted as a fraction of the input DNA for each reaction, subtracting the ChIP-PCR backgrounds. We
measured ER ChIP-PCR DNA in cells transfected with a scramble control (scr) or an siCCND1 (siD1) oligonucleotide. Transfectants were
treated with vehicle control (V) or estradiol (E). For each site, the bars depict the ER signal for scramble plus vehicle (scr), scramble plus E2
(scr E2), siCCND1 plus vehicle (siD1), and siCCND1 plus E2 (siD1 E2). Three conserved, canonical estrogen binding elements identified in the
UCSC genome browser were compared; these sites are indicated according to the nucleotide distance downstream of the transcription start site
of the B isoform of the progesterone receptor. (E) Stable knockdown of cyclin D1 reduces PR mRNA levels. We stably reduced cyclin D1
expression in T47D cells by expressing a lentiviral shRNA construct in pooled transfectants selected using puromycin. Changes in cyclin D1 and
progesterone receptor mRNAs are shown as fold changes in mRNA levels compared to those of pooled control cells containing the
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cluding Sp1 (39), AP1 at90 from the PR B transcription start
site (TSS) (33), a G/A GATA5 breast cancer risk polymor-
phism (17), an Sp1-ERE half-site (33), a second AP1 at 745
(38), an RNA polymerase II binding site (6), and a rat pro-
moter site that responded to E2 (20). We used ChIP-PCR to
directly evaluate effects of estradiol and CCND1 on estrogen
receptor binding to these candidates (Fig. 4B). According to
the results of our chromatin immunoprecipitation studies,
none of these previously proposed alternative promoter ele-
ments showed increased estrogen receptor binding with estro-
gen stimulation. Two of the eight sites showed a significant
decrease in estrogen receptor binding after cyclin D1 knock-
down, and they were located at the core progesterone receptor
promoter sites for the B isoform (centered at 60) and the A
isoform (centered at 658).
The Genome Browser of the University of California at
Santa Cruz (UCSC) identifies three highly conserved, canoni-
cal estrogen receptor binding sites ([agGtCAnnnTGaCct])
(ERE 1–ERE 3) in the progesterone receptor gene that are
located at 51,200, 79,800, and 95,585 nucleotides downstream
of the transcription start site for the B isoform of the proges-
terone receptor (Fig. 4C) (21). A recent genome-wide screen-
ing showed that only the site at 95585 binds the estrogen
receptor in response to estrogen treatment (6). We used ChIP
together with quantitative PCR (ChIP-PCR) to directly eval-
uate effects of estradiol and CCND1 on these candidate sites
(Fig. 4D). We first confirmed that estradiol induced anti-ER-
bound DNA only for the ERE 3 site, which also showed the
highest levels of ER-specific binding. The siCCND1 small
inhibitory RNA decreased ER binding at all three sites, but
only the binding to the ERE 3 site was both stimulated by
estrogen and blocked by siCCND1.
To confirm the ChIP experiment results, we stably expressed
an shRNA that targets exon 2 of cyclin D1 in T47D cells. This
shRNA knocked cyclin D1 mRNA levels down by 50%, which
resulted in a decrease of PR mRNA to 10% of its levels in
control cells (Fig. 4E). We then evaluated DNA-protein inter-
actions across the 240 nucleotides spanning the ERE 3 region
by the use of electrophoretic mobility shift assays (EMSA). We
first compared the DNA binding activity of lysates harvested
from the vector control to that of CCND1 shRNA cells for 13
overlapping oligonucleotides that spanned the entire region.
Cyclin D1 knockdown significantly altered binding at the ca-
nonical nucleotide 95585 ERE site (Fig. 4F) without altering
binding at other adjacent sites (not shown). Using estrogen
stimulation and cold-competitor oligonucleotides, we con-
firmed the estrogen response and sequence specificity of this
ERE site.
We cloned a 1.3-kb genomic segment containing ERE 3 into
standard luciferase reporter gene vectors to determine
whether it could enhance transcription. Using PCR cloning, we
placed it downstream of luciferase in reporter vectors lacking
a heterologous promoter (pGL2-Basic [pGL2N]) and contain-
ing a heterologous promoter (pGL2 promoter [pGL2P]). We
transfected reporter constructs together with either a scramble
control siRNA (scramble) or siCCND1 (Fig. 5A and B) into
T47D cells. In addition, we cotransfected the reporter con-
structs with either a control expression vector or a CCND1-
expressing vector (pCCND1) (Fig. 5C and D). We performed
these experiments using cells treated with vehicle alone (Fig.
5A and C) and cells treated with estradiol (Fig. 5B and D). The
PR 3 UTR sequences did not significantly increase luciferase
expression in the absence of promoter sequences (Fig. 5A
[pGL2N-UTR versus pGL2N]). However, they caused a 6-fold
increase in expression when combined with a heterologous
promoter (Fig. 5A [pGL2P-UTR versus pGL2P]).
Estradiol stimulated the PR UTR when combined with a
heterologous basal promoter, taking estradiol’s inhibition of
the isolated promoter into consideration (compare Fig. 5A and
B). This estradiol responsiveness of the PR UTR was best seen
in the experiments using scramble control oligonucleotides and
siCCND1 to determine whether decreased cyclin D1 could
block the 3 PR UTR’s enhancing function (Fig. 5A and B).
Importantly, siCCND1 decreased PR 3 UTR-driven reporter
activity to 78% of control levels in vehicle-treated control cells
and to 42% of controls in estradiol-treated cells. Transfection
of a cyclin D1 expression vector increased the reporter activity
of the PR 3 UTR (Fig. 5C and D). It doubled pGL2P-UTR
activity in vehicle-treated cells and increased pGL2P-UTR re-
porter activity nearly 3-fold in the presence of estradiol treat-
ment.
To determine whether these effects were related to cyclin
D1-CDK interactions, we compared the effect of a wild-type
cyclin D1 to that of a cyclin D1 K112E mutant that cannot
interact with CDK4/CDK6 (15) (Fig. 5E). The KE mutant had
effects equivalent to those of the wild-type cyclin D1 on the
pGL2P-UTR reporter vector containing the 3 UTR of the
progesterone receptor in vehicle-treated cells. Interestingly,
the KE mutation abrogated wild-type cyclin D1’s 2-fold in-
crease in activation of the pGL2P-UTR in estradiol-treated
cells. Finally, a reporter construct containing a 3-fold repeat of
an isolated estrogen receptor binding sequence (ERE) (14) did
not respond in the same manner to the CCND1 expression
plasmid or to siCCND1 (Fig. 5F). Taken together, these assays
identify the 3 UTR region of the PR gene as a unique cyclin
D1- and estrogen-responsive element.
A 3 estrogen/cyclin D1-responsive enhancer element inter-
acts with the progesterone receptor A and B promoters. We
parent pLKO vector (Vec). We used qRT-PCR to monitor mRNA levels as described in Materials and Methods. (F) Stable knockdown of cyclin
D1 reduces binding to the canonical estrogen receptor binding site in the 3 ERE of the progesterone receptor gene. We used electrophoretic
mobility shift assays to monitor protein binding to an oligonucleotide containing the estrogen response element sequences 95,585 nucleotides
downstream of the PR transcription start site. Protein binding to the oligonucleotide probe was evaluated in lysates harvested from the vector
control cells (LKO) in the absence and presence of estradiol (E2). Levels of binding to the radiolabeled probe were compared using lysates
harvested from the cells expressing the cyclin D1 knockdown shRNA (KD) in the absence and presence of estradiol (E2). The specificity of the
binding was evaluated using a 200-fold excess of unlabeled probe (585), unlabeled 585 oligonucleotide containing a mutation in the ERE (585),
an unlabeled smaller oligonucleotide containing the core ERE sequence (585core), and an unlabeled core oligonucleotide containing the
ERE-inactivating mutation (EREcore).
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further analyzed the 1.3-kb PR 3 UTR region to determine
whether it functions as an enhancer (Fig. 6). We first combined
the 3 UTR region with the progesterone receptor’s own pro-
moter region (17) and found that it activated reporter expres-
sion from the PR promoter 13-fold more potently than it
activated the heterologous basal promoter in the pGL2 vector.
We next found that its core 238 nucleotides that are conserved
from lizards to humans are nearly as functional as the full
1.3-kb region when combined with the progesterone receptor’s
own promoter. The functions of both the full 1.3-kb UTR
region and its core 238 nucleotides were independent of ori-
entation, and increasing the core sequence copy number in-
FIG. 5. A 3 estrogen-responsive enhancer in the progesterone receptor gene is regulated by cyclin D1. (A and B) Cloning of the 3 ERE of
the PR gene downstream of a basal promoter-luciferase construct activates transcription that responds to estrogen and cyclin D1. We cloned 1.3
kb of the PR 3 UTR into luciferase reporter vectors. We performed reporter assays using T47D cells in the absence and presence of estradiol for
24 h. Knockdown efficiency for the siRNAs for these experiments is shown in Fig. 4A. Levels of firefly luciferase from the progesterone receptor
plasmids are compared to those of an internal pCMV-renilla control (FF/RL ratio). Means 
 standard errors of the results determined in three
replicated experiments are shown. Reporter activity levels in cells transfected with a scrambled control siRNA (scramble) and an siCCND1
(siCCND1) in the presence of vehicle (A) or estradiol (B) were compared. Results for a pGL2-basic (pGL2N) vector with no promoter, a reporter
containing a basal promoter (pGL2P), the basal vector containing the PR gene 3 UTR (pGL2N-UTR), and the PR gene 3 UTR region cloned
in the promoter reporter (pGL2P-UTR) are shown. (C and D) Activity levels determined using the same reporters were further compared between
cells transfected with an empty vector control (vector) or an expression plasmid for cyclin D1 (pCCND1) in the presence of vehicle (C) or estradiol
(D). (E) The 3 ERE of the PR gene is activated by cyclin D1 in a CDK4/CDK6-independent manner in the absence of estrogen and in a
CDK4/CDK6-dependent manner in its presence. We evaluated the effect of wild-type cyclin D1 (D1) and the KE cyclin D1 mutant (D1 KE) on
the 3 UTR region by use of the PR gene 3 UTR region cloned in the promoter reporter (pGL2P-UTR). Transfections were performed as
described for panels C and D. We further compared cells transfected with vehicle-treated cells (left panel [Vehicle]) to cells treated with estrogen
(right panel [Estradiol]). (F) Changes in cyclin D1 levels do not change levels of expression from a reporter plasmid containing a 3 isolated
estrogen response element. Standard reporter vector containing a basal promoter activated by a 3 estrogen receptor binding element (14) was
cotransfected with a scrambled control siRNA (scr) and an siCCND1 (siD1), and reporter activity in the presence of estradiol was determined (left
panel). The same reporter was cotransfected with an empty vector control (Vec) or an expression plasmid for cyclin D1 (pc-D1 [right panel]).
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FIG. 6. Definition of a core 238-nucleotide segment in DNA encoding part of the progesterone receptor 3 UTR as a position- and
orientation-independent enhancer of expression. To construct the plasmid diagrams, we obtained a luciferase (Luc) reporter vector containing the
progesterone receptor promoter (PR) from the region spanning positions 711 to 822 (17), which is designated hPR AB in the figure. It
contained both the PR isoform B transcription start site at 0 and the PR A isoform transcription start site at 751, as indicated in the diagrams
of the various plasmids in the left column of the figure. We cloned the full 1.3-kb PR UTR region downstream of the luciferase in hPR AB in both
orientations to produce hPR AB-UTR and hPR AB-RTU. The UTR orientation is indicated by the triangular point added to the rectangle in each
diagram. We then cloned a 238-bp highly conserved central element-containing region (CER) from the 3 UTR (positions 95435 to 95672 relative
to the B form transcription start site) into the hPR AB plasmid in both orientations (producing hPR AB-CER and hPR AB-REC). We further
introduced two mutations in the canonical ERE sequence in the CER portion of hPR AB-CER to interrupt estrogen receptor binding as predicted
by previous studies (10) to make hPR AB-CER1 and hPR AB-CER2. Finally, we cloned a 3-fold repeat of the CER segment downstream and
upstream of the hPR AB plasmid to evaluate the effects on gene expression of increasing its copy number. We compared these constructs to a
smaller set of UTR and CER modifications of the pGL2 basal promoter reporter plasmid (pGL2P). (A) Element-specific activation compared to
that seen with the parent hPR AB or pGL2P promoter vectors in the absence of estradiol. The indicated plasmids were transfected into T47D cells,
and firefly luciferase expression was normalized to a cotransfected cytomegalovirus (CMV)-renilla luciferase construct. The activation effects of
the individual elements were then plotted as the fold increases in expression from the element-containing plasmid compared to that of the
promoter-only plasmids (hPR AB for the dark-gray columns and pGL2P for the light-gray columns). Values shown represent means 
 standard
errors of the results of three determinations for each experiment. The CER retains most of the 3 UTR activity, and tandem repeats of the CER
further stimulate the PR promoter. The indicated mutations in the core canonical estrogen response element abolish activation by the enhancer.
(B) Element-specific stimulation of the 3 UTR region of the progesterone receptor gene and its central element region by estradiol. The indicated
plasmids were transfected as described for panel A, in the absence and presence of estradiol. The responses to estradiol of the individual elements
were then plotted as the fold increases in expression from the element-containing plasmid between the vehicle-treated cells and cells treated with
estradiol. Values shown represent means 
 standard errors of the results of three determinations for each experiment.
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creased its function. The core 238-nucleotide element re-
sponded to estrogen in a position-independent manner. Finally,
mutations of its ERE binding sequence (ATGTCATGCTGA
CCT) to AgGgCATGCTGACCT or ATGTCATGC-----T re-
duced its enhancement of promoter function and its estrogen
response.
To evaluate cyclin D1’s effects on PR isoform-specific pro-
moters, we cloned the PR 3 UTR enhancer into reporter
constructs containing isolated PR A and B promoters (17)
(Fig. 7). We repeated cotransfections with cyclin D1 and
siCCND1. The PR A promoter is somewhat responsive to changes
in CCND1 expression on its own, and its function and response
to CCND1 are markedly increased by the addition of the PR 3
UTR enhancer sequences (Fig. 7A and B). Using isoform-
specific qRT-PCR, we also found that PR A mRNA decreases
accounted for most of the response to siCCND1 (55% of levels
in scramble-transfected controls). A strong reaction of PR A to
cyclin D1 changes was seen in response to both siCCND1 and
CCND1 overexpression. Interestingly, the PR B promoter was
not responsive to CCND1 on its own, but siCCND1 blocked
estrogen-induced increases when the PR B promoter was com-
bined with the PR 3 UTR enhancer (Fig. 7C and D). While
the reporter gene result differs somewhat from the behavior of
endogenous PR B (Fig. 4A), the added estrogen in these ex-
periments likely accounts for the difference. The PR gene 3
UTR enhancer therefore activates both PR isoform promot-
ers, with the A isoform showing greater interaction with cyclin
D1 and the B isoform being more responsive to estrogen.
Cyclin D1 knockdown decreases progesterone receptor ex-
pression in additional breast cancer cells. Having identified a
direct link between CCND1 levels and PR expression, we
sought to determine whether additional breast cancer cell lines
exhibited this CCND1 control of PR (Fig. 8). siCCND1 trans-
fection effectively reduced CCND1 protein levels in five addi-
tional cell lines (Fig. 8A), and PR was consequently reduced in
two of them, namely, the ZR75-1 and MCF7 cell lines. We
further found that IER3 and ETV5 levels also decreased in
response to CCND1 and PR decreases in the same two cell
lines. We used isoform-specific qRT-PCR to analyze PR iso-
form transcripts (Fig. 8B). We found that levels of the com-
bined PR A-and-B transcript, predominately, those of PR A-
specific mRNA, decreased in response to the siCCND1
knockdown in ZR75-1 and MCF7 cells. Finally, we evaluated
the response of the 3 UTR enhancer to cyclin D1 expression
in MCF 7 cells (Fig. 8C). As described for the T47D cells,
decreased cyclin D1 levels decreased the PR UTR enhancer
activity, increased cyclin D1 levels increased the PR UTR
enhancer activity, and the cyclin D1 K112E mutant remained
active in these cells.
DISCUSSION
While studies of cyclin D1 have long established its primary
role in cell cycle regulation, additional studies examining its
effects on gene expression have suggested that it might have
additional CDK4/CDK6-independent effects (29, 52). Since
those previous studies initially relied on reporter assays, en-
dogenous targets were not identified (51). By identifying genes
associated with cyclin D1’s effects on tumor invasion, we re-
cently identified genes that responded to the combination of
estrogen and cyclin D1 (48). Given that these genes responded
to this combination, we treated cyclin D1 transgenic mice with
estrogen. We now report that the combination of estrogen and
constitutive cyclin D1 expression increased progesterone re-
ceptor expression, increased PR function, increased PR-target
gene expression, and increased PR effects (Fig. 1 to 3).
The phenotypic changes accompanying cyclin D1 overex-
pression shown here, together with the previously reported
FIG. 7. The 3 ERE of the PR gene differentially activates PR
isoform-specific promoters, which respond to estrogen and cyclin D1.
We combined the PR 3 UTR (UTR) with PR reporters containing its
individual A and B promoters. The 3 UTR was cloned into PR A
(hPRA) and PR B (hPRB) plasmids as indicated. We performed
reporter assays in the absence (left panels) and presence (right panels)
of estradiol as described in the previous figure legends. (A) Levels of
activity induced by the hPRA and hPRA-UTR reporters were com-
pared in the presence of a scrambled control siRNA (scramble) and in
the presence of the siCCND1 oligonucleotide (siCCND1). (B) Levels
of activity induced by the hPRA and hPRA-UTR reporters were com-
pared in the absence (vector) and presence (pCCND1) of transfected
cyclin D1. (C) Levels of activity induced by the hPRB and hPRB-UTR
reporters were compared in the presence of a scrambled control
siRNA (scramble) and in the presence of the siCCND1 oligonucleo-
tide (siCCND1). (D) Levels of activity induced by the hPRB and
hPRB-UTR reporters were compared in the absence (vector) and
presence (pCCND1) of transfected cyclin D1. FFluc/Renluc, levels of
firefly luciferase from the progesterone receptor plasmids compared to
those of an internal pCMV-renilla control.
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phenotype of cyclin D1 knockout mice, support the idea that
the PR is a cyclin D1 target. The histologic appearance of
cyclin D1 transgenic mammary glands treated with estrogen
(Fig. 1) strongly resembles glands in mice constitutively ex-
pressing additional PR (41, 42). The failure of mammary de-
velopment during pregnancy in cyclin D1 null mice (43) is
nearly identical to the loss of mammary development in PR
null mice (28). In contrast, mammary glands in mice lacking
the ER do not resemble glands in mice lacking cyclin D1 (11).
Our data suggest that cyclin D1 may act both as a cell cycle
mediator of ovarian hormone activity and as a developmental
switch that increases in mammary glands to augment their
effects on mammary development. This model implies an ad-
ditional potential explanation for the decreased tumor forma-
tion seen in erbB2 and ras transgenic mice when they are cyclin
D1 null (50), since the decreased tumorigenesis could result
from loss of PR function and/or loss of cell cycle control.
Notably, a progesterone receptor antagonist blocks tumorigen-
esis in BRCA mutant mice (34).
After years of studies of estrogen regulation of the PR gene,
a clear estrogen-responsive enhancer has not yet been identi-
fied in its sequences (31). Various studies of PR promoter
proximal elements particularly failed to identify canonical es-
trogen receptor binding elements. Here we show that a 238-
nucleotide sequence in the 3 UTR of the progesterone gene is
a classic estrogen-responsive enhancer. It contains a canonical
estrogen receptor binding element whose sequence is highly
conserved. The homology plot in Fig. 4C shows that this ele-
ment is the most highly conserved region of the progesterone
receptor gene, excluding its coding exons. The estrogen recep-
tor binds this sequence in an estrogen-dependent manner. In
reporter experiments, it activates estrogen-regulated expres-
sion of both the PR promoter and a heterologous promoter. Its
activation is independent of position and orientation and in-
creases with increased copy numbers (Fig. 6).
Given the importance of progesterone receptor expression,
exploring unique features of its enhancer is important to un-
derstand how ovarian hormones regulate breast development
and carcinogenesis. We have shown using ChIP, siRNA knock-
downs, and cyclin D1 overexpression studies that this enhancer
is uniquely responsive to cyclin D1. Its response to cyclin D1 is
FIG. 8. Progesterone receptor expression is blocked by a small
inhibitory RNA for cyclin D1 in breast cancer cells in addition to the
T47D cells used for the previous four figures, and decreases in cyclin
D1 sensitize cell lines to both antiestrogen and antiprogesterone treat-
ments. (A and B) Progesterone receptor expression responds to
CCND1 knockdowns in several human breast cancer cell lines. (A) Im-
munoblot experiments were performed using the indicated gene prod-
ucts and 50 g of lysates harvested 48 h after transfection as described
for Fig. 4. Cyclin D1 levels differed between the cell lines, with those
toward the left of panel A showing generally higher levels, as is con-
sistent with the known results of 11q13 amplifications in ZR75-1 and
CAMA cells. siCCND1 knocked down CCND1 protein levels in all cell
lines tested. As we observed with respect to T47D cells, CCND1
knockdown decreased levels of PR isoform A in MCF7 and ZR75-1
cells. Similar losses of candidate CCND1-target genes were seen in
parallel for IER3 and ETV5 in these cell lines. An actin loading
control is shown. (B) The indicated human breast cancer cell lines
were transfected with scramble (Sc) or siCCND1 (Si). Levels of iso-
form AB- and B-specific transcripts of the progesterone receptor were
measured using equal amounts of reverse-transcribed cDNA via iso-
form-specific qRT-PCR. Isoform A levels were derived by subtracting
B from AB levels. The means and standard errors for fold changes
from scramble to siCCND1 transfectants for each of the indicated cell
lines are indicated. (C) The 3 UTR of the PR gene responds to cyclin
D1 in MCF 7 cells. The pGL2P-UTR vector was transfected into MCF
7 cells together with a scramble control RNA (scr), siCCND1 (siD1),
an empty vector control (vec), an expression plasmid for cyclin D1
(D1), and the plasmid expressing the K112E mutant of cyclin D1 (KE).
Reporter gene expression measured as described above is plotted as
the ratio of the firefly luciferase (FF) in the PR reporter to the CMV-
renilla control reporter.
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independent of the presence of CDK4/CDK6 in the absence of
estrogen, although its response is dependent on the presence
of CDK4/CDK6 in the presence of estrogen (Fig. 5E). Estro-
gen and cyclin D1 additively stimulate its function, potentially
explaining their combined in vivo effects on mammary devel-
opment. In contrast, a reporter construct containing a 3-fold
repeat of the canonical estrogen response element did not
respond to cyclin D1 decreases or increases (Fig. 5F). Impor-
tantly, the estrogen receptor binding element was required for
the PR enhancer’s function both for promoter activation and
for estrogen response (Fig. 6).
Our results provide the first in vivo identification of a gene
containing an estrogen receptor binding element (ERE) that
responds to cyclin D1 in the manner previously proposed (29,
52). On the other hand, we did not confirm that cyclin D1
could activate an isolated ERE (Fig. 5F), demonstrating that
other elements in the PR enhancer are required for its cyclin
D1 responsiveness. Our results suggest that cyclin D1 has at
least two mechanisms responsible for activation of the PR
enhancer. Further, we could not demonstrate direct binding of
cyclin D1 to the PR enhancer in ChIP experiments, largely
because available cyclin D1 antibodies immunoprecipitate sev-
eral nonspecific bands. Given our results, the PR enhancer
obviously contains additional DNA binding elements likely to
contribute to its unique response to cyclin D1. Brown and
colleagues have found that FOXA1 binding in combination
with the ER defines enhancer-driven lineage-specific transcrip-
tion for a number of ER-targeted enhancers (5). The PR 3
UTR enhancer region lacks a FOXA1 binding site, although
the results of another genome-wide ChIP scan previously sug-
gested that FOXA1 can bind in this region (25). Additionally,
there are no E2F sites in the PR enhancer, and PR is not
known to be regulated through the cell cycle. Rather, a tran-
scription regulatory element search (TRES) of the core region
of this PR enhancer identified conserved sites for AP4, E47,
Sox-5, and HOXA9 (18). Since the PR enhancer is now a
well-characterized endogenous target sequence that is regu-
lated by both increased and decreased cyclin D1 levels, iden-
tification of combinations of transcription factors involved in
its regulation would be important to gain a better understand-
ing of mechanisms explaining cyclin D1’s role in gene expres-
sion control.
The role of progesterone in breast cancer pathogenesis has
long been controversial (24). Progesterone’s contribution to
rapid signaling through the activity of mitogen-activated pro-
tein kinases is important in the deregulation of breast cancer
cell proliferation (8). Hormone replacement therapies that
combine estrogen with progesterone clearly demonstrate that
these hormones together can promote breast carcinogenesis
(7). We now show that cyclin D1’s tight association with the
ER and PR status of breast cancers may result from the com-
bination of ovarian hormone control of cyclin D1’s cell cycle
effects together with a feed-forward regulation of PR expres-
sion by cyclin D1 and estrogen. This mechanism would provide
a strong selective pressure for increasing cyclin D1 expression
in hormone receptor-positive breast cancers. We further show
that this regulation is encoded in a novel 238-nucleotide en-
hancer in the progesterone receptor gene. Identification of
additional regulators of this enhancer should offer important
insights into cyclin D1’s CDK4/CDK6-independent transcrip-
tional effects and could potentially identify therapeutic targets
whose manipulation could inhibit the combined effects of cy-
clin D1 and estrogen in cases of breast cancer.
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